5 QUESTIONS EVERY BREAST CANCER PATIENT SHOULD ASK TO HELP PREVENT LYMPHEDEMA
Recognising Risk Factors for Breast-Cancer related Lymphoedema (BCRL)
MAJOR TREATMENT-RELATED RISK FACTORS
PATIENT AND DISEASE-RELATED RISK FACTORS
- Axillary Lymph Node Dissection (ALND): The strongest single risk factor; having more lymph nodes removed (10 or more) significantly increases risk (20-53% risk with ALND vs. 5-17% with sentinel node biopsy)."
- Postoperative Radiotherapy: Regional lymph node radiation increases relative risk by 1.8-2 times, especially when combined with ALND.
- Postoperative Wound Complications: Wound infection or axillary lymphocele multiplies odds 3-4 fold.
- Neoadjuvant Chemotherapy: Neoadjuvant chemotherapy is Increasingly recognized as a risk factor, with contemporary studies
PATIENT AND DISEASE-RELATED RISK FACTORS
- High Body Mass Index (BMI ≥30): Obesity nearly quadruples risk; 32% of obese patients develop BCRL vs. 10.5% with BMI <30.
- Hypertension and Diabetes: These comorbidities are associated with higher risk, though evidence is variable.
- Advanced Breast Cancer Stage (Stage III): Patients with advanced disease have 1.7 times higher risk compared to those with early-stage disease.
- Race: Black and other minoritized populations have a higher risk of lymphedema, independent of other factors. Studies show disparities in prevalence and outcomes, emphasizing a need for tailored patient education and surveillance.
- Genetic Predispositions: Variations in certain genes and biomarkers may increase individual risk, suggesting personalized approaches in the future.
- Chemotherapy and Neoadjuvant Therapy: Systemic therapies are linked to increased risk, though this is lower than surgical or obesity-related risk factors.
- Long Duration of Axillary Drainage (>7 days): Associated with higher risk of developing BCRL.
- Physical Strain or Injury: Overuse, trauma, or infection of the ipsilateral arm may provoke onset.
- Lack of Breast Reconstruction: Some evidence suggests absence of immediate reconstruction may elevate risk.
- Most cases develop within three years post-treatment, most commonly in the first year.
- Risk is cumulative -multiple treatment and patient factors substantially elevate likelihood
- Early education, regular arm volume monitoring, and prompt intervention can reduce incidence and severity.
- If a patient has any of these risk factors, initiate ongoing surveillance, regular arm volume and/or bioimpedance monitoring and empower with self-monitoring and prevention education
